Blog

ORLANDO, FLORIDA / ACCESS Newswire / July 3, 2025 / RedChip Companies will air interviews with Fathom Holdings, Inc. (Nasdaq:FTHM) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, July 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

• FTHM: https://www.redchip.com/assets/access/fthm_access

• FBLG: https://www.redchip.com/assets/access/fblg_access

In an exclusive interview, Marco Fregenal, CEO of Fathom Holdings, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company’s disruptive approach to real estate services through its proprietary, technology-driven platform. Fregenal highlights Fathom’s flat-fee commission model, which empowers agents to retain more of their earnings while enabling industry-leading retention and rapid national expansion. With operations in 43 states and a network of over 14,700 agents, Fathom is scaling efficiently through its virtual model, integrated ancillary services, and strategic acquisitions, including the recent addition of My Home Group. He also addresses Fathom’s innovative Bitcoin strategy and strong financial performance, including a 32% year-over-year revenue increase in Q1 2025, positioning the Company to capture additional market share amid an improving housing market.

Pete O’Heeron, CEO of FibroBiologics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to spotlight the company’s pioneering work in fibroblast-based cell therapies. O’Heeron discusses the advantages of fibroblasts over traditional stem cells, highlighting their regenerative and immunomodulatory properties, scalability, and safety profile. He outlines the Company’s robust pipeline, led by CYWC628 for diabetic foot ulcers, which is slated to enter a Phase 1/2 clinical trial in Australia later this year. Additional programs, including CybroCell™ for degenerative disc disease and CYMS101 for multiple sclerosis, target multi-billion-dollar markets and are supported by promising preclinical and early human data. With over 240 issued and pending patents, a recently completed cGMP-compliant cell bank, and a seasoned leadership team, FibroBiologics is advancing a scalable, off-the-shelf platform poised to transform treatment for chronic diseases and deliver significant long-term value to shareholders.

FTHM and FBLG are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About Fathom Holdings Inc.

Fathom Holdings Inc. is a national, technology-driven real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings to brokerages and agents by leveraging its proprietary cloud-based software, intelliAgent. The Company’s brands include Fathom Realty, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. For more information, visit www.FathomInc.com.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip’s products and services, please visit:

https://www.redchip.com/corporate/investor_relations

“Discovering Tomorrow’s Blue Chips Today”™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com

–END–

SOURCE: RedChip Companies, Inc. (Media Suite)

View the original press release on ACCESS Newswire

• Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated urinary tract infections

• PIVYA expected to be available in the U.S. in the 4th quarter of 2025.

LONDON, UK / ACCESS Newswire / July 3, 2025 / UTILITY therapeutics Ltd. (UTILITY), a biotechnology company focused on the development of PIVYA (pivmecillinam 185 mg tablets), a penicillin class antibacterial approved by the U.S. Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (uUTI), today announced that it has been acquired by Alembic Pharmaceuticals, Inc. (Alembic).

PIVYA marked the first antibiotic in approximately 20 years to earn FDA approval for uUTI, a common bacterial infection that afflicts millions of women annually. The FDA approved PIVYA in April 2024 for use in female patients 18 years of age and older with uUTI caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. PIVYA has a unique mechanism of action that targets the cell wall of gram-negative bacteria.

Additional U.S. prescribing information about PIVYA can be found at www.pivya.com.

“We are thrilled that Alembic Pharmaceuticals understands the clinical and commercial value of PIVYA and will bring this proven treatment to female patients in need across the U.S.,” said Tom Hadley, President and CEO of UTILITY therapeutics. “With current therapies failing and the armament of uUTI antibiotics perilously thin, PIVYA provides U.S. clinicians with a new and effective treatment option that has a long safety record. We are grateful for the support of our Board of Directors and investors, including the AMR Action Fund, whose collective support was instrumental in helping us obtain FDA approval for PIVYA.”

The UTILITY therapeutics Ltd. Board of Directors and Observers includes:

• Alan S. Roemer, MBA, MPH, Chairman of the Board

• Morten Sommer, PhD, Co-Founder

• Rasmus Toft-Kehler, PhD, Co-Founder

• Andrew Davis, Independent Director

• Larry Edwards, Independent Director

• Thomas Hadley, President & CEO

• Henry Skinner, PhD, MJur, MBA, AMR Action Fund

• Tero Wennberg, PhD, Observer, LEO Pharma

• Henni-Karoliina Ropponen, PhD, Observer, AMR Action Fund

“The acquisition of UTILITY and the commercialization of PIVYA are important steps in Alembic’s strategic goal to provide branded pharmaceutical products to the U.S. healthcare market,” said Craig Salmon, President of Alembic Pharmaceuticals, Inc. “PIVYA will further enhance Alembic’s ability to build long-term value by combining global research, regulatory, and manufacturing strengths with a sharpened focus on specialty segments. Alembic plans to make PIVYA available in the U.S. in the 4^th quarter of 2025.”

“I am excited to see Alembic drive the commercialization of PIVYA, which is uniquely positioned to help millions of American women with urinary tract infections,” said Dr. Morten Sommer, Professor of microbiology at the Technical University of Denmark, and co-founder and board member of UTILITY therapeutics. “With a novel mechanism of action, not previously deployed in the U.S., PIVYA can become a cornerstone of the treatment of urinary tract infections based on its first-line positioning in the Infectious Disease Society of America treatment guidelines. On behalf of the co-founders, investors, and Board of Directors, we are excited that PIVYA will help address the societal impact of the uUTI disease burden in women.”

About PIVYA (pivmecillinam oral tablets 185mg)

PIVYA, an oral prodrug of mecillinam, is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.

Mecillinam demonstrated in vitro activity against Enterobacterales in the presence of some beta-lactamases and extended-spectrum beta-lactamases (ESBL) of the following groups: CTX-M, SHV, TEM, AmpC. The inhibitory action of mecillinam on PBP-2 results in low cross-resistance with certain beta-lactams. The frequency of resistance to mecillinam in E. coli range from
8×10^-8 to 2×10^-5 when exposed to 32-256 times MIC.

PIVYA has been proven safe and effective in three clinical trials with the most common Adverse Reactions Occurring in ≥1% of Patients Receiving PIVYA (Adjusted for Study Size); Nausea (4.3%), Diarrhea (2.1%), Vulvovaginal candidiasis (1.8%), Genital pruritus (1.8%), and Headache (1.4%).

PIVYA demonstrated strong response in three controlled clinical trials comparing different PIVYA dosing regimens to placebo (Trial 1), to another oral antibacterial drug (Trial 2), or to ibuprofen (Trial 4) evaluated the efficacy of pivmecillinam for the treatment of uUTI. Efficacy was assessed in the Microbiological Intent-to-Treat (micro-ITT) population which included all randomized subjects with a positive baseline urine culture defined as ≥10⁵ colony-forming-units (CFU)/mL of a uropathogen where CFU count was available and no more than 2 species of microorganisms, regardless of colony count, and no baseline pathogen was non-susceptible to the active comparator. The composite response rates (composite endpoint of clinical cure and microbiological response), as well as clinical cure and microbiological response rates of the recommended 185 mg three times daily dosing regimen.

Composite Response Rates (Clinical Cure and Microbiological Response) at TOC in the uUTI trials (Micro ITT Population)

	Composite Response Rates (Clinical Cure and Microbiological Response)
Trial 1	PIVYA N=137, n (%)	Placebo N=134, n(%)	Difference (95% CI)
	85 (62)	14 (10)	52 (41,62)
Trial 2	PIVYA N=127, n (%)	Cephalexin N=132 n(%)
	91 (72)	100 (76)	-4(-16, +7)
Trial 4	PIVYA N=105, n (%)	Ibuprofen N=119 n(%)
	69 (66)	26 (22)	44 (31, 57)

Clinical Cure Rates (Micro-ITT Population)

	Clinical Cure Rates
Trial 1	PIVYA N=137, n (%)	Placebo N=134, n(%)	Treatment Difference (95% CI)
	87 (64)	31 (23)	40 (29, 52)
Trial 2	PIVYA N=127, n (%)	Cephalexin N=132 n(%)
	105 (83)	112 (85)	-2 (-12, +8)
Trial 4	PIVYA N=105, n (%)	Ibuprofen N=119 n(%)
	81 (77)	45 (38)	39 (27, 52)

Microbiological Response Rates (Micro-ITT Population)

	Microbiological Response Rates
Trial 1	PIVYA N=137, n (%)	Placebo N=134, n(%)	Treatment Difference (95% CI)
	119 (87)	35 (26)	61 (51,71)
Trial 2	PIVYA N=127, n (%)	Cephalexin N=132 n(%)
	97 (76)	106 (80)	-4 (-15, +7)
Trial 4	PIVYA N=105, n (%)	Ibuprofen N=119 n(%)
	78 (74)	64 (54)	7, 34)

Contraindications

• Serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to PIVYA or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins).

• Primary or secondary carnitine deficiency resulting from inherited disorders of mitochondrial fatty acid oxidation and carnitine metabolism such as carnitine transporter defect or other inborn errors of metabolism (e.g., methylmalonic aciduria, or propionic academia).

• Acute porphyria.

Warnings and precautions

• Hypersensitivity Reactions: Serious hypersensitivity reactions including anaphylaxis have been reported in patients receiving PIVYA. If hypersensitivity reactions occur, discontinue treatment with PIVYA and institute appropriate therapy.

• Severe Cutaneous Adverse Reactions (SCAR): Acute Generalized Exanthematous Pustulosis (AGEP), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported with PIVYA. Monitor closely and discontinue PIVYA at the first signs or symptoms of SCAR or other signs of hypersensitivity.

• Carnitine Depletion: In patients at risk for reductions in serum carnitine, e.g., significant renal impairment or decreased muscle mass, consider alternative antibacterial therapies. PIVYA is not recommended when prolonged antibacterial treatment is necessary. Avoid concurrent treatment with valproic acid, valproate or other pivalate-generating drugs due to increased risk of carnitine depletion.

• Clostridioides difficile-Associated Diarrhea (CDAD): This has been reported with nearly all systemic antibacterial agents, including PIVYA. Evaluate if diarrhea occurs.

• Interference with Newborn Screening Test: Treatment of a pregnant individual with PIVYA prior to delivery may cause a false positive test for isovaleric acidemia in the newborn as part of newborn screening. Prompt follow-up of a positive newborn screening result for isovaleric acidemia is recommended.

About UTILITY therapeutics Ltd.

UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections (UTI). Pivmecillinam is an oral prodrug of mecillinam that has been approved by the FDA for the treatment of women with uncomplicated urinary tract infections. PIVYA has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases. Mecillinam, an intravenous (IV) formulation, may be developed as a first-line therapy for complicated UTI (cUTI) in the hospital setting.

For more information, contact

David Cobb, Alembic Pharmaceuticals
david.cobb@alembicusa.com
908-552-583

SOURCE: Utility Therapeutics Ltd.

View the original press release on ACCESS Newswire

Demonstrating sustained growth and demand in the Canadian market

MIAMI BEACH, FLORIDA / ACCESS Newswire / July 3, 2025 / LQR House Inc. (the “Company” or “LQR House”) (NASDAQ:YHC), a niche ecommerce platform specializing in the spirits and beverage industry, is pleased to announce that Of The Earth Distribution Corp., an Ontario-based importer of premium craft spirits, has placed its third major purchase order, totaling 176 cases of SWOL Tequila.

The Company believes that this latest order reflects continued momentum across both trade and consumer channels in the Ontario market. The Company also introduced a refreshed 9-bottle case format and an enhanced bottle design, both aimed at increasing shelf visibility and reinforcing the brand’s premium positioning.

The growing volume supports LQR House’s broader expansion strategy into Canada’s hospitality industry. In the past quarter alone, Of The Earth Distribution has onboarded 40 new on-premise accounts, spanning licensed restaurants, bars, and clubs throughout Ontario. At the same time, direct-to-consumer sales have shown steady growth, signaling strong product-market fit and growing brand recognition.

“This new order is both a response to market demand and a signal of where we’re headed as a company,” said Jason Pucci, Founder and CEO of Of The Earth Distribution Corp. “The updated case size supports greater efficiency for our trade partners, while the new bottle design represents a significant step forward in aligning our visual identity with the premium quality of the product inside.”

Sean Dollinger, CEO of LQR House, added “I’ve always said-three is a streak. In a category as saturated and competitive as tequila, where new brands seem to appear daily, we consider this level of repeat demand a clear validation of our strategy and the product’s impact. It’s incredibly rewarding to watch something resonate so strongly in the market, and I believe this momentum is just the beginning of where we’re headed.”

About LQR House Inc.

LQR House intends to become a prominent force in the wine and spirits e-commerce sector, epitomized by its flagship alcohol marketplace, cwspirits.com. This platform seamlessly delivers a diverse range of emerging, premium, and luxury spirits, wines, and champagnes from esteemed retail partners like Country Wine & Spirits. Functioning as a technology-driven hub, LQR House utilizes software, data analytics, and artificial intelligence to elevate consumer experience. CWSpirits.com stands out as the go-to destination for modern, convenience-oriented shoppers, providing a curated selection of alcohol products delivered to homes across the United States. Beyond its role in an e-commerce sector, LQR House is a marketing agency with a specialized focus on the alcohol industry. The Company measures campaign success by directly correlating it with sales on CWSpirits.com, demonstrating a return on investment. Backed by an influential network of around 460 figures in the alcohol space, LQR House strategically drives traffic to CWSpirits.com, enhancing brand visibility. LQR House intends to disrupt the traditional landscape of the alcohol industry, driven by its dedication to providing an unparalleled online purchasing experience and delivering tailored marketing solutions.

About Of The Earth Distribution Corp.

Of The Earth Distribution Corp. is a premier distributor of fine spirits in Canada, committed to delivering top-quality products to the Canadian market. With a focus on exceptional service and client satisfaction, the company works with global partners to bring world-class spirits to Ontario and beyond. The company is licensed through the LCBO and operates as a boutique importer focused on culturally rooted, sustainably produced spirits. The company is committed to working directly with heritage producers and delivering premium products to both the hospitality trade and discerning consumers across Ontario.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Shareholders can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. Forward-looking statements contained in this press release are made only as of the date of this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in other reports and documents that the Company files from time to time with the United States Securities and Exchange Commission (the “SEC”). You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the headings “Risk Factors”. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in other reports and documents that the Company files from time to time with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. References and links to websites have been provided as a convenience, and the information contained on such websites has not been incorporated by reference into this press release.

Investor and Media Contact:

info@lqrhouse.com

SOURCE: LQR House

View the original press release on ACCESS Newswire

Additional Units Set for Upcoming Delivery

HOUSTON, TX / ACCESS Newswire / July 3, 2025 / Envirotech Vehicles, Inc. (NASDAQ:EVTV) (“Envirotech,” “EVT”, or the “Company”) is pleased to announce the completed delivery of another EVT Bumble Bee electric school bus to Texas independent school districts. The bus was delivered this week to the Kopperl Independent School District (“Kopperl ISD”) in Kopperl, Texas.

Under the U.S. Environmental Protection Agency’s Clean School Bus (“CSB”) Program-which was established to provide $5 billion over five years to replace existing fleets with zero-emission buses- $8,570,000 was awarded to cover the production and distribution of 25 electric school buses by Envirotech to school districts in Texas and Arkansas.

“We have now completed four bus deliveries in the past 15 days and expect to see growth in this segment continue to ramp up,” remarked Jason Maddox, President and Interim Chief Financial Officer of Envirotech. “We express great thanks to the EPA for the Clean School Bus Program and look forward to additional school bus deliveries this year as well as the opportunity to potentially access additional grant funding to further expand this vertical in 2026.”

The EVT Bumble Bee fast-charging 100% electric school bus has a proven range of up to 150 miles on a single charge with zero emissions and no noise pollution. It represents a significant improvement over conventional fossil fuel powered buses:

• Zero tailpipe emissions-students, drivers, and members of the community will be exposed to significantly less harmful diesel emissions like particulate matter and nitrogen oxides.

• Reduced greenhouse gas emissions compared to diesel school buses.

• Reduced maintenance costs due to regenerative braking and no engine or exhaust system.

• Potential for reduced fuel costs compared to diesel depending on electricity costs.

• Quiet, clean operation.

Kopperl ISD Superintendent Katrina Adcock was present when Envirotech delivered the Bumble Bee electric school bus to the district. “The bus was delivered this morning. It is super cool! Exciting times for Kopperl ISD and Bosque County.”

For more information on the CSB Program please visit the EPA program website at: https://www.epa.gov/cleanschoolbus

Business owners and potential strategic partners interested in learning about Envirotech’s technology offering are invited to visit the Company’s website and can contact the Company through the website at https://evtvusa.com/contact-evtv/.

About Envirotech Vehicles
Envirotech Vehicles, Inc. (NASDAQ:EVTV) is a technology company dedicated to revolutionizing the electric vehicle landscape by designing and manufacturing electric commercial vehicles that offer sustainable, efficient, and cost-effective transportation solutions. Committed to driving the future of mobility, Envirotech is pushing the boundaries of innovation and sustainability.

For more information, visit www.evtvusa.com

Cautionary Statement Regarding Forward-Looking Statements
Statements made in this press release that relate to future plans, events, financial results, prospects, or performance are forward-looking statements and include, but are not limited to, statements regarding the proposed delivery of additional EVT electric school buses, future grants under the CSB Program towards EVT electric school buses, and the intended benefits and performance of EVT electric school buses. While they are based on the current expectations and assumptions and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions, and other factors that could cause actual results to differ materially from the expectations expressed in this press release. Important factors that could cause actual results to differ materially from current expectations include, among others, Envirotech’s ability to successfully deliver electric vehicles, Envirotech’s ability to maintain compliance with The Nasdaq Stock Market LLC listing requirements, and the other risks and uncertainties disclosed in reports filed by Envirotech with the Securities and Exchange Commission, all of which are available online at www.sec.gov. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “will,” “estimated,” “planned,” “expected,” “believes,” “strategy,” “opportunity,” “anticipated,” “outlook,” “designed,” and similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Envirotech undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances, or unanticipated events.

CONTACT:
Envirotech Vehicles, Inc.
Merrick Alpert, Chief Communications Officer
Telephone: (870) 970-3355
Email: merrick@evtvusa.com

SOURCE: Envirotech Vehicles, Inc.

View the original press release on ACCESS Newswire

A Major Step Toward Precision Diagnostics with the Implementation of CaloPix®

PARIS, FRANCE / ACCESS Newswire / July 3, 2025 / Tribun Health, European leader in AI-enhanced digital pathology, is proud to announce that the Versailles Hospital Center, the supporting institution of GHT 78 Sud, has selected its imaging platform, CaloPix®, to support the digital transformation of its pathology department.

This decision represents a strategic milestone in modernizing diagnostic services within the French public healthcare system. Through this project, the Versailles Hospital Center joins a growing network of pioneering institutions leveraging Tribun Health’s technologies to optimize workflows, enhance diagnostic quality, and prepare for the integration of artificial intelligence.

“We are honored by the trust that the Versailles Hospital Center has placed in us,” said Jean-François POMEROL, CEO of Tribun Health. “This choice reflects a shared commitment to innovating for more effective, collaborative, and patient-centered healthcare.”

“The selection of CaloPix® is fully aligned with our digital transformation strategy,” explained Dr. Claire GLASER, Head of the Pathology Department at the Versailles Hospital Center. “We were impressed by the solution’s user-friendliness, performance, and the quality of support offered by Tribun Health’s teams. This project, developed in collaboration with the GHT Yvelines Nord, marks a key step for the future of our specialty in the region, particularly regarding AI and collaborative work. It also enhances our integration into APHP’s expert networks equipped with the same software.”

CaloPix® will be deployed throughout the pathology department to support primary diagnostics, interdisciplinary collaboration, and the future integration of AI solutions. Known for its intuitive interface, high performance, and adaptability to the evolving needs of hospital structures, the platform is open and interoperable.

This project is fully aligned with the digital strategy of the Versailles Hospital Center and GHT 78 Sud, in collaboration with GHT Nord, and reflects a national plan aimed at modernizing and digitizing healthcare infrastructures. It is also part of a strong regional initiative and will serve as an interoperability foundation within the GHTs of the Yvelines region.

About Tribun Health

Tribun Health, recognized under the French Tech 2030 label, is a global leader in digital pathology, offering award-winning solutions that improve workflow efficiency, diagnostic accuracy, and patient outcomes. We assist hospitals and laboratories in transitioning from glass slide pathology to fully digital solutions, leveraging AI and data-driven technology to enhance precision and reduce turnaround times. Our mission is simple: to ensure every cancer patient receives a timely and informed diagnosis-because every moment counts. By advancing pathology with cutting-edge innovations, we are shaping the future of cancer care. For more information, visit Tribun Health and follow us on LinkedIn and X.

Contact Information

Andreia Beyer
VP, Global Marketing & Managing Director, North America
abeyer@tribun.health
+1 (416) 565-0474

SOURCE: Tribun Health

View the original press release on ACCESS Newswire

With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets

MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company’s proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation.

Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects.

“These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential,” said Erez Aminov, Chairman and CEO of MIRA. “We believe the drug’s ability to match morphine’s pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It’s another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain.”

Study Overview and Key Findings

Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat’s paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume.

Key findings:

• Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline levels.

• Its analgesic effect was equivalent to morphine, the standard opioid comparator in the study.

• No sedation or inflammatory swelling was observed with Mira-55 treatment.

Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound’s long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development.

These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55’s selective pharmacological profile.

“Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs,” said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. “Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today’s standards.”

Strategic Fit Within MIRA’s Pain Portfolio

Mira-55 complements Ketamir-2, MIRA’s clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain.

“With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated,” added Aminov. “We’re advancing each asset methodically, and we’re energized by the momentum we’ve built across the pipeline.”

Corporate Update on SKNY Merger

MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction.

“We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation,” said Aminov. “This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth.”

Next Steps

MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones.

About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.

Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact:
Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

Path of Liberty will offer active, off-duty, and retired military members and their families special complimentary tickets for prime viewing.

NEW YORK, NY / ACCESS Newswire / July 2, 2025 / Path of Liberty: That Which Unites US, a powerful public art installation made possible by The Soloviev Foundation, will welcome active, off-duty, and retired military members and their families this Independence Day at 8:30pm as the nation begins the official countdown to America’s 250th birthday. Situated along the East River, the installation offers a meaningful backdrop for the celebration and live simulcast of the annually anticipated Macy’s Fireworks Show. To reserve complimentary tickets for this private catered event, please visit poljuly4.splashthat.com.

LEFT: Path of Liberty: That Which Unites US, an immersive public art installation at Freedom Plaza made possible by the Soloviev Foundation, features larger-than-life photography and videos of Americans from across the country. Courtesy of C&G Partners, Exhibition and Experience Designer.

RIGHT: Lieutenant Mickey Kross is a retired New York City firefighter whose miraculous survival during the September 11, 2001 attacks has become a powerful testament to resilience and courage. A member of Engine Company 16, Kross was assigned to the North Tower that morning. He and his team had reached the 23rd floor to assist with evacuations when the South Tower collapsed. Moments later, as the North Tower began to fall, Kross was buried beneath the rubble. Trapped for nearly three hours, he survived by taking shelter in a corner, with his helmet shielding him from falling debris. In the aftermath, Kross played an active role in the recovery efforts at Ground Zero. The helmet that helped save his life is now preserved in the National September 11 Memorial & Museum, serving as a symbol of bravery and endurance. Courtesy of The Soloviev Foundation.

High resolution installation and subject images can be downloaded here

“This year’s 4th of July begins a historic journey toward America’s 250th birthday,” said Michael Hershman, a decorated Army veteran and CEO of Soloviev Group. “We are proud that Path of Liberty offers a space where neighbors, veterans, and visitors can come together to reflect on our shared values and honor the diverse voices that continue to shape our country.”

Stretching from 38th to 41st Street along First Avenue, the six-acre immersive installation transforms the cityscape with a larger-than-life tribute to the founding ideals that unite us. With vibrant visuals and emotional storytelling, Path of Liberty: That Which Unites US offers a fresh and inclusive lens on what it means to be American.

The installation, by exhibition and experience design firm C&G Partners and directed by Cannes-selected filmmaker Daniella Vale, features 41 towering interactive screens showcasing striking photography and short films. This brings to life the personal stories of 55 Americans – veterans, librarians, farmers, Indigenous leaders, astronauts, and others-whose lived experiences illuminate the shared principles of liberty, equality, and perseverance.

The exhibit is free and open to the public every Thursday through Saturday from 8:00 PM to 11:00 PM, with walk-ups welcome and advance reservations available at pathoflibertynyc.com.

Path of Liberty: That Which Unites US expands on The Soloviev Foundation’s commitment to bringing the community together through art that encourages contemplation, nurtures connection, and inspires hope.

TOP LEFT: Petty Officer 1st Class Steven Edgar is a Mass Communication Specialist in the U.S. Navy, stationed at Naval Air Station Joint Reserve Base (NAS JRB) New Orleans. In this role, he produces and manages public affairs content, including photography, videography, and written communications that highlight the base’s missions and personnel. Courtesy of The Soloviev Foundation.

TOP RIGHT: Ariel Broussard is a dedicated service member in the U.S. Navy, currently stationed in New Orleans. With a strong commitment to national service, Broussard plays a vital role in supporting the Navy’s operations while contributing to the city’s vibrant military community. Courtesy of The Soloviev Foundation.

BOTTOM LEFT: Noah Currier is a decorated Marine veteran and the founder of Oscar Mike, a nonprofit dedicated to supporting disabled veterans through mental health services and adaptive sports. After returning from Iraq, Currier sustained a life-changing spinal cord injury in a vehicle accident. Rather than letting adversity limit him, he turned his experience into a mission to uplift fellow veterans. Through Oscar Mike, he provides rehabilitation and empowerment programs that help wounded service members regain their independence and sense of purpose. Courtesy of The Soloviev Foundation.

BOTTOM RIGHT: Al “Mr. G” Godlewski enlisted in the Army during World War II in 1943, serving in England and France with the 140th Finance Disbursement Section. He narrowly escaped a torpedo attack and played a key role in ensuring 30,000 soldiers received their pay. Now at 100 years old, he remains active, enjoying time with family, reading, jigsaw puzzles, and the occasional martini. Courtesy of The Soloviev Foundation.

ABOUT PATH OF LIBERTY: THAT WHICH UNITES US

Encompassing more than six-acres on Manhattan’s East Side from 38th to 41st Street on First Avenue, the large-scale exhibition provides a visual and narrative journey of the founding principles of the United States, framed by stunning portraits and immersive landscapes. Made possible by the Soloviev Foundation, Path of Liberty: That Which Unites US will welcome guests and present an exploration of both the achievements and ongoing challenges of American democracy. Through powerful, large-scale environmental portraits and interactive elements, visitors will leave with a deeper understanding of the country’s past, present, and future. Please visit pathoflibertynyc.com and follow @pathoflibertynyc on Instagram and Facebook for more information.

ABOUT THE SOLOVIEV FOUNDATION

The Soloviev Foundation is the charitable giving arm of the Soloviev Group, dedicated to supporting the efforts of those working across humanitarian, environmental, and educational causes. The Foundation’s gifts go to both large, long-established institutions addressing global crises and concerns, and smaller, hyperlocal organizations serving the populations in need within their communities. For more information, visit solovievfoundation.org.

Contact Info:
info@dujour.com
646-710-4494

SOURCE: DuJour Media

View the original press release on ACCESS Newswire

Well-Known Entrepreneur Hired for Key Leadership Role

SCOTTSDALE, ARIZONA / ACCESS Newswire / July 2, 2025 / Phone Ninjas, the automotive industry’s leader in dealership-specific coaching and training, is proud to spotlight Ashley Vlastaris, one of the newest additions to its growing team of Sales Executives. In just five months, Ashley has already made a strong impression, bringing fresh energy, a dealer-first mindset, and a relentless focus on driving measurable results.

“Ashley really hit the ground running,” said Chris Vitale, Chief Operating Officer at Phone Ninjas. “From day one, she’s been deeply engaged with our dealer partners, asking the right questions, listening carefully, and working hard to understand each store’s unique challenges. That curiosity and drive are exactly what make a great Sales Executive.”

Already, she’s been instrumental in supporting dealership sales teams, understanding showroom dynamics, and helping tailor training solutions that improve performance metrics like appointment set, show, and buy rates.

“When you’re working with dealers, it’s not about selling a product – it’s about solving problems,” said Ashley. “They’re busy, they’re juggling priorities, and they need real support. That’s what drew me to Phone Ninjas – we’re not here to add noise; we’re here to make things work better.”

As Phone Ninjas continues its rapid expansion, team members like Ashley represent the next generation of automotive coaching, bringing passion, data-savvy insight, and an unwavering commitment to dealer success.

About Phone Ninjas

Founded in 2010, Phone Ninjas helps businesses master all client-facing communications with one goal in mind: better conversations that lead to better results. Through expertly designed ongoing coaching and training programs that support the sales, service, and parts departments, Phone Ninjas helps dealers turn all client interactions into appointments that show and buy – the right way.

SOURCE: Phone Ninjas

View the original press release on ACCESS Newswire

SAN RAMON, CA / ACCESS Newswire / July 2, 2025 / CMG Financial, one of the nation’s top mortgage lenders, is proud to announce that two of its Executive Vice Presidents, Courtney Thompson and Susan Walker, have been named to HousingWire’s 2025 Women of Influence list. This prestigious award honors women in housing who are making notable contributions to both their organizations and the industry at large. With their innovative thinking, leadership, and vision for the future, Courtney and Susan exemplify what it means to lead with impact.

“This year’s honorees include mentors, innovators, and community leaders,” wrote Lesley Collins, HousingWire Editor’s Choice Awards Program Manager. “Many are paving the way for future generations through mentorship, volunteer initiatives, and by serving on boards that influence key industry practices. Collectively, their efforts are shaping not only their companies but also the communities they serve and the future of housing itself.”

Courtney Thompson, EVP of Servicing at CMG, has spent the past year tackling one of the biggest challenges in mortgage servicing: building a modern, borrower-first platform from the ground up. Tasked with developing a fully in-house servicing solution, she’s led a bold effort to move beyond outdated legacy systems and create something built for today’s consumer. Under her leadership, the platform has taken shape as a fully connected ecosystem-one that keeps loan officers involved post-close, gives borrowers access to personalized tools and insights, and reshapes how homeowners interact with their loans. It’s not just a tech project-it’s a reinvention of the servicing experience, and it’s already drawing attention across the industry.

Susan Walker, EVP of Corporate Efficiency at CMG, has spent the past year acting as the voice of the loan officer, translating feedback from top performers into meaningful enhancements to CMG’s core platforms, CLEAR and Byte. By embedding herself directly with Product and Technology teams, she helped identify workflow inefficiencies and delivered rapid-fire improvements that drove adoption, boosted morale, and aided in bolstering these systems into competitive strengths. Her impact earned her a seat on the Executive Management Team, where she now oversees Post Closing, Vendor Management, and Product. In this new role, she continues to lead with the same hands-on, cross-functional approach, streamlining operations, reducing costs, and identifying upstream efficiency and alignment opportunities. Her results speak volumes: a West Division that topped $3B in volume, over 100 strategic hires, and a culture that now embraces technology more than ever before. Susan’s work isn’t just about optimizing systems, it’s about building a smarter, more resilient CMG.

“Courtney and Susan are both exceptional leaders and trusted partners who bring passion, clarity, and a deep sense of responsibility to everything they do,” said Paul Akinmade, Chief Strategy Officer at CMG Financial. “They care deeply about their work, their teams, and the future of this company. What stands out is how they bring people together to drive meaningful change, from the first moments of origination all the way through to servicing.”

CMG congratulates both honorees and thanks HousingWire for recognizing the leadership, excellence, and trailblazing impact of women across housing finance. To read their full Women of Influence profiles, click here.

About CMG

CMG Mortgage, Inc. NMLS ID# 1820 (www.nmlsconsumeraccess.org)(http://www.cmghomeloans.com ) is a well-capitalized mortgage lender founded in 1993. Founder and CEO, Christopher M. George, was Chairman of the Mortgage Bankers Association in 2019. CMG makes its products and services available to the market through three distinct origination channels including retail lending, wholesale lending, and correspondent lending. CMG currently operates in all states, including the District of Columbia, and holds approvals with FNMA, FHLMC, and GNMA. CMG is widely known throughout the mortgage banking and housing markets for responsible lending practices, industry and consumer advocacy, product innovation, and operational efficiency.

About HousingWire

HousingWire is the most influential source of news and information for the U.S. mortgage and housing markets, boasting a readership that spans lending, servicing, investments, and real estate market participants, as well as financial market professionals. With over 10 million annual unique visitors, HousingWire is the community for mortgage and housing professionals to engage and connect. Industry decision-makers rely on us to Move Markets Forward.

Media Contact

Annaugh Madsen
Phone: (667) 260-6360
Email: amadsen@cmgfi.com

SOURCE: CMG Financial

View the original press release on ACCESS Newswire